title: [Growth hormone receptor antagonist in the treatment of acromegaly].
abstract: Exploration of construction, function and interaction of human growth hormone and growth hormone receptor in details resulted in the innovation of the new growth hormone receptor antagonist, pegvisomant. Pegvisomant with different mechanism of action extended the tools of medical management of acromegaly. Importance of the novel treatment modality is high. In one hand the necessity of the strict control of growth hormone/insulin-like growth factor-I axis has been proven regarding the mortality of the disease. On the other hand, despite the use of all current modes of treatment (surgery, radiotherapy, dopamine agonists, somatostatin analogs), a significant cohort of patients with acromegaly remains inadequately controlled. Pegvisomant has been registered in 2004. Since 2006, it has been used in Hungary for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. Clinical use of pegvisomant in the treatment of acromegaly is effective, well tolerated, and safe, based on international Acrostudy database. In order to improve the efficacy of therapy clinical trials started with pegvisomant and somatostatin analog combination treatment. Evidence of several further effects of the growth hormone/insulin-like growth factor-I axis suggests other potential uses of growth hormone receptor antagonists.
authors.affiliation: Honvédkórház-Állami Egészségügyi Központ II. Belgyógyászati Osztály Budapest Podmaniczky u. 109-111. 1062. ehubina@gmail.com
authors.forename: Erika
authors.initials: E
authors.lastname: Hubina
authors.forename: Agnes
authors.initials: A
authors.lastname: Tóth
authors.forename: Gábor László
authors.initials: GL
authors.lastname: Kovács
authors.forename: Judit
authors.initials: J
authors.lastname: Dénes
authors.forename: László
authors.initials: L
authors.lastname: Kovács
authors.forename: Miklós
authors.initials: M
authors.lastname: Góth
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000236:Adenoma / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D000595:Amino Acid Sequence; D017024:Chemotherapy, Adjuvant; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006814:Hungary; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D008969:Molecular Sequence Data; D010911:Pituitary Neoplasms / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors*
chemical_list: D008565:Membrane Proteins; D011986:Receptors, Somatotropin; C405010:delta-hGHR; D019382:Human Growth Hormone; C406545:pegvisomant